Bio Developments

Pic:getty/drmicrobe

Building an mRNA giant: Moderna’s 7 priorities for 2023

By Rachel Arthur

mRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range...

Pic:getty/richarddrury

BioNTech and OncoC4 team up on novel checkpoint antibody

By Rachel Arthur

BioNTech and OncoC4 have announced a worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications....

Pic:getty/andrejrostek

Novartis releases long-term Zolgensma data

By Rachel Arthur

Novartis has presented new data which ‘underscore the transformational and sustained benefit’ of spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec): with treated children maintaining motor milestones after 7.5 years.

Pic:getty/aventtr

Biotage acquires Astrea Bioseparations

By Rachel Arthur

Biotage will acquire Astrea Bioseparations, a chromatography solutions provider, from Gamma Biosciences: extending its chromatography franchise into the bioprocessing market for biologics and advanced therapeutic customers.

Pic:getty/antoniosolano

Syena sets out to pioneer TCR NK cell therapy

By Rachel Arthur

New company Syena says it has the potential to create the next generation of cell therapy: combining the safety, potency and scalability of natural killer (NK) cells with the ability of T cell receptors (TCR) to target intracellular tumor antigens.

Pic:getty/totojang

CGT Catapult boost for UK life science campus

By Rachel Arthur

The Cell and Gene Therapy Catapult (CGT Catapult) has confirmed its involvement in the development of a new £900m ($1,097m) life science campus in Stevenage, UK: which is set to become one of the largest in Europe.

Pic:getty/andrewbrookes

Janssen discontinues Phase 3 HIV vaccine trial

By Rachel Arthur

Janssen’s experimental HIV vaccine regimen was found to be safe but ineffective in the Phase 3 Mosaico clinical trial: and as a result the company is discontinuing the study.

Pic:getty/adamgault

Moderna to acquire OriCiro Genomics

By Rachel Arthur

mRNA specialist Moderna will acquire OriCiro Genomics K.K, a pioneer in cell-free DNA synthesis and amplification technologies, for $85m.